In summary, TACE combined with donafenib and a PD-1 inhibitor demonstrated good clinical efficacy, durable antitumor responses, and significantly prolonged PFS and OS in patients with advanced HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.